Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
01-03 April, 2025
Peptide-Based Therapeu...Peptide-Based Therapeutics Summit
Not Confirmed
Not Confirmed
01-03 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
01-03 April, 2025
Peptide-Based Therapeu...Peptide-Based Therapeutics Summit
Industry Trade Show
Not Confirmed
01-03 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
19 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/19/3045786/0/en/Century-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html
21 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/21/3012514/0/en/Century-Therapeutics-Announces-Investigator-Initiated-Phase-1-2-Trial-of-its-iPSC-derived-iNK-Cell-Therapy-CNTY-101-in-B-cell-Mediated-Autoimmune-Diseases-Sponsored-by-Internationa.html
17 Dec 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/bms-keeps-axing-deals-inked-under-old-leadership-time-culling-cell-therapy-pacts-century
26 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/26/2987336/0/en/Century-Therapeutics-to-Present-at-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html
05 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/05/2974998/0/en/Century-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html
05 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/05/2974963/0/en/Century-Therapeutics-Announces-Upcoming-Poster-Presentations-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html
Details:
CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, intended for moderate to severe systemic lupus erythematosus.
Lead Product(s): CNTY-101
Therapeutic Area: Immunology Brand Name: CNTY-101
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2025
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Century Announces Phase 1/2 Trial of iNK Cell Therapy CNTY-101 in Autoimmune Diseases
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, intended for moderate to severe systemic lupus erythematosus.
Product Name : CNTY-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 21, 2025
Details:
Century intends to use the net proceeds to support the expansion of CNTY-101, a CD19-targeting iNK cell therapy, currently being evaluated in a clinical trial in B-cell malignancies.
Lead Product(s): CNTY-101
Therapeutic Area: Immunology Brand Name: CNTY-101
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Bain Capital Life Sciences
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 04, 2024
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Bain Capital Life Sciences
Deal Size : $60.0 million
Deal Type : Private Placement
Century Therapeutics Expands Autoimmune Pipeline Supported by $60M and Clade Acquisition
Details : Century intends to use the net proceeds to support the expansion of CNTY-101, a CD19-targeting iNK cell therapy, currently being evaluated in a clinical trial in B-cell malignancies.
Product Name : CNTY-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 04, 2024
Details:
CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived NK cells with a CD19-directed CAR and designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells and NK cells.
Lead Product(s): CNTY-101,Undisclosed
Therapeutic Area: Oncology Brand Name: CNTY-101
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2023
Details : CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived NK cells with a CD19-directed CAR and designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells...
Product Name : CNTY-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 02, 2023
Details:
CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, administered via Intravenous Infusion, intended for moderate to severe systemic lupus erythematosus.
Lead Product(s): CNTY-101
Therapeutic Area: Immunology Brand Name: CNTY-101
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, administered via Intravenous Infusion, intended for moderate to severe systemic lupus erythematosus.
Product Name : CNTY-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 12, 2023
Details:
Century will be responsible for discovery and preclinical development of CNTY-104, an iPSC-derived allogeneic cell therapies for hematologic and solid tumors. Bristol Myers Squibb will be responsible for clinical development and commercialization of first two programs.
Lead Product(s): CNTY-104
Therapeutic Area: Oncology Brand Name: CNTY-104
Study Phase: DiscoveryProduct Type: Cell and Gene therapy
Sponsor: Bristol Myers Squibb
Deal Size: $3,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration October 01, 2022
Details : Century will be responsible for discovery and preclinical development of CNTY-104, an iPSC-derived allogeneic cell therapies for hematologic and solid tumors. Bristol Myers Squibb will be responsible for clinical development and commercialization of firs...
Product Name : CNTY-104
Product Type : Cell and Gene therapy
Upfront Cash : $150.0 million
October 01, 2022
Details:
CNTY-101 is the first allogeneic cell product candidate with six genetic modifications incorporated using sequential rounds of CRISPR-mediated homologous recombination and repair that has received IND clearance by the FDA.
Lead Product(s): CNTY-101,Undisclosed
Therapeutic Area: Oncology Brand Name: CNTY-101
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 25, 2022
Details : CNTY-101 is the first allogeneic cell product candidate with six genetic modifications incorporated using sequential rounds of CRISPR-mediated homologous recombination and repair that has received IND clearance by the FDA.
Product Name : CNTY-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 25, 2022
Details:
CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch.
Lead Product(s): CNTY-101,Undisclosed
Therapeutic Area: Oncology Brand Name: CNTY-101
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2022
Century Therapeutics to Present at the SITC 37th Annual Meeting
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch.
Product Name : CNTY-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 10, 2022
Details:
CNTY-102 simultaneously target CD19 and CD79b designed to increase depth and durability of response by eliminating effect of CD19 antigen loss that has been observed as factor limiting treatment durability while targeting CD79b.
Lead Product(s): CNTY-102
Therapeutic Area: Oncology Brand Name: CNTY-102
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2022
Lead Product(s) : CNTY-102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Century Therapeutics to Present at the ASGCT 25th Annual Meeting
Details : CNTY-102 simultaneously target CD19 and CD79b designed to increase depth and durability of response by eliminating effect of CD19 antigen loss that has been observed as factor limiting treatment durability while targeting CD79b.
Product Name : CNTY-102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 05, 2022
ABOUT THIS PAGE